Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.
News|Articles|February 16, 2026
Common Pain Relievers Lead US Medication Use Trends
Author(s)Maggie L. Shaw
Fact checked by: Julia Bonavitacola
These new data show that 64.8% of US adults take at least 1 prescription medication each year.
Advertisement
Advertisement
New national survey data show that over-the-counter (OTC) and prescription medication use are nearly identical in prevalence, with common pain relievers leading the list, as well as that nearly two-thirds of
Related to this article
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
The NPS index, ranging from –100 to +100, serves as a proxy for customers’ willingness to recommend products and services they themselves have used.
The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
Advertisement
Advertisement